ReviewTargeted oncology2017

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.

Olivier Bylicki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.